Plain-English translation of NCT07261306 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Psoriasis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , an oral medication, works as well as or better than —another oral medication commonly used to treat psoriasis. Both medications work through different mechanisms to reduce the inflammation and skin symptoms of psoriasis. The study will compare how effective these treatments are and how safe they are for people with moderate to severe plaque psoriasis.
Psoriasis affects millions of people worldwide, and while topical treatments (creams and ointments) help some patients, many people need stronger oral medications. This medication represents a newer approach to treating psoriasis, and researchers want to understand how it compares to standard treatments in terms of safety and effectiveness.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to take one of the two oral medications as a daily pill. You will have regular visits with the study team to monitor how well the treatment is working, check for any side effects, and perform blood tests to ensure your liver and kidney function remain safe. The study will track improvements in your skin symptoms over time to determine which treatment is most effective and best tolerated.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Pakistan
Phase
Safety & dosing
Sponsor
Lahore General Hospital
Enrollment target
~75 participants
Started
August 2025
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Maryam Fatima, Mbbs
Lahore General Hospital, Lahore
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.